The Mark of Gideon

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Retrieved on: 
Giovedì, Dicembre 21, 2023
Partnership, Food, Antigen, Hoʻokipa, Sale, Arenavirus, The Mark of Gideon, Common stock, Investigational New Drug, Equity, HIV, LCMV, Prospectus, Gilead Sciences, Security (finance), Pharmaceutical industry

In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.

Key Points: 
  • In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.
  • The agreement with Gilead replaces the stock purchase agreement that Hookipa entered into with Gilead in 2022.
  • Following the completion of the stock purchase, Gilead’s ownership in HOOKIPA increased to 18,759,465 shares, or approximately 19.4% of HOOKIPA’s outstanding shares of Common Stock.
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Retrieved on: 
Lunedì, Novembre 20, 2023
SIV, Food, Antigen, IND, Antibody, Arenavirus, FDA, The Mark of Gideon, Simian immunodeficiency virus, Vaccination, NPJ, Animal, HIV, Vaccine, LCMV, Gilead Sciences, Viral load

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Key Points: 
  • HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
  • The analyses published were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as a surrogate to HIV.
  • One vector is based on lymphocytic choriomeningitis virus (LCMV) as its arenaviral backbone; another vector is based on Pichinde virus (PICV).
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

Retrieved on: 
Domenica, Ottobre 22, 2023
Neoplasm, The Mark of Gideon, E6, ESMO, Progression-free survival, DCR, Pembrolizumab, LCMV, Congress, Arenavirus, E7, CPI, Memorial Sloan Kettering Cancer Center, HPV16, COVID, Immune system, Oncology, ORR, ELISPOT, RECIST, DCO, Safety, Patient, Pharmaceutical industry, Vaccine

All evaluable patients were alive at the data cutoff (DCO), and the median follow-up time at DCO was 8.3 months.

Key Points: 
  • All evaluable patients were alive at the data cutoff (DCO), and the median follow-up time at DCO was 8.3 months.
  • Importantly, results showed significant activation of antigen-specific CD8+ T cells, the body’s primary driver of tumor killing activity.
  • Out of 17 patients with available peripheral blood mononuclear cells (PMBC) samples, all patients showed an increase of tumor antigen-specific circulating HPV16+ CD8+ T cells.
  • These data represent a doubling of the 19 percent ORR reported for pembrolizumab alone1 and are consistent with previously reported HB-200 data.

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Retrieved on: 
Mercoledì, Ottobre 18, 2023
Hepatocyte, The Mark of Gideon, Hepatitis B virus, The Journal of Infectious Diseases, Immunization, Antigen, Liver, Arenavirus, Journal, Gilead Sciences, Vaccination, Disease, Hepatitis, Safety, Infection, HBV, Vaccine, Pharmaceutical industry

The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.

Key Points: 
  • The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.
    HB-400 is an alternating, 2-vector non-replicating arenaviral therapeutic vaccine for the treatment of chronic hepatitis B.
  • It uses the Lymphocytic Choriomeningitis Virus and Pichinde Virus as arenaviral backbones, with each expressing three highly conserved hepatitis B virus antigens.
  • HB-400 is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead Sciences, Inc.
  • “The lack of curative therapies for chronic hepatitis B infection is a significant barrier to addressing the global burden of disease,” said Joern Aldag, Chief Executive Officer at HOOKIPA.

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

Retrieved on: 
Martedì, Maggio 9, 2023
Antigen, HIV, Clinical trial, Arenavirus, Hepatitis B, The Mark of Gideon, IND, Safety, Pharmaceutical industry, Vaccine

”More importantly, the start of the HB-400 trial is an important milestone for the hepatitis B community as hepatitis B remains an area of critical unmet need.

Key Points: 
  • ”More importantly, the start of the HB-400 trial is an important milestone for the hepatitis B community as hepatitis B remains an area of critical unmet need.
  • It uses the lymphocytic choriomeningitis virus and pichinde virus as arenaviral backbones, with each expressing three highly conserved hepatitis B virus antigens.
  • The hepatitis B program is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead.
  • HOOKIPA is responsible for advancing the investigational HIV therapeutic vaccine through completion of a Phase 1b clinical trial.